posted
Where did you hear that? Looks like this stock is gearing up for a huge PR on Monday or Tuesday
Posts: 109 | Registered: May 2004
| IP: Logged |
I am not selling this time my shares at 0.015, having a sell at 0.02.
-------------------- Investment Is Important, but Knowing where to make an Investment in your life makes all Difference Posts: 280 | Registered: Jan 2006
| IP: Logged |
posted
Maybe I will sell half of my shares at 0.015, this time too.... and wait for a dip again.
-------------------- Investment Is Important, but Knowing where to make an Investment in your life makes all Difference Posts: 280 | Registered: Jan 2006
| IP: Logged |
posted
I think its dangerous to flip at this point. Do you think the factory would be commissioned if the company didn't get NAFDAC approval, absolutely not. I believe the company has the approval and is just waiting to release it with hopefully some figures. We should all thank sites like these we got this news ahead of time. So far Southpick guys predictions are right on could possibly see .26 cents easily in the near future.
Posts: 415 | From: Toronto, Ontario, Canada | Registered: Aug 2003
| IP: Logged |
posted
I left for an appointment and this thing was down.. I was starting the wonder if I should of bought back the shares I flipped yesterday at .0144 (bought back at .0110)Now I am glad I did... It should be a nice ride from here since close was at .015 with Bid and Ask being the same!
-------------------- All men's gains are the fruit of venturing.
~Herodotus Posts: 339 | From: Southern California | Registered: Aug 2005
| IP: Logged |
posted
XKEM ---alot of accumaltion has been going the last few weeks. IMO this stock is gonna explode soon. I'm hoping for a 10 bagger from these levels short term. Been a great stock to daytrade as well, everytime it dips it goes right back up. This news that has not been put out as a pr yet is huge!!
28 million dollar commitment from Nigerian Government, Huge biotech play, XKEM drug going in to mass production.
March 3rd, 2006 Obasanjo to launch locally produced sickle cell drug
President Olusegun Obasanjo will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder. PATIENCE OGBE Abuja
The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN
The drug NIPRISAN (HEMOXIN(TM), which is at present, undergoing final stage of registration with NAFDAC is a phyto-pharmaceutical drug for the treatment of patients suffering from Sickle Cell Disease (SCD). SCD is an insidious and painful genetic blood disorder often resulting in death at an early age.
Science and Technology Minister, Turner Isoun who disclosed this in Abuja noted that location of the factory in Nigeria would further crash the price of sickle cell drugs in Nigeria.
Isoun stated that Niprisan (HEMOXIN(TM)) was a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary process. The licensor of the technology is the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria.
Nigeria is said to have the highest sickle cell disease population in the world ranging from four to six million representing roughly three to five percent of the country's population.
Isoun spoke at the inaugural meeting of the Ministers’ Council for the National Biotechnology Development Agency (NABDA) where he also called on the government to involve more laboratories for the control and analysis of the bird flu menace.
On the situation of bio technology in Nigeria, he called on the stockholding agencies to ensure that Nigeria benefits from the judicious and safe use of modern biotechnology.
"Biotech is a gold mine and important to this nation. Almost every Nigerian is affected by the operations of biotech. To be able to achieve all these, we will require the concerted political will and a focused leadership drive. It is therefore the collective responsibility of all of us key stakeholders of modern biotechnology to join forces in realizing this vision.
It is my belief that this collective mission will not jeopardize our separate mandates but will promote the effective coordination of our effort towards achieving the same ultimate goal."
To achieve the nation’s targets in biotech, the Director General of the National Biotechnology Development Agency (NABDA), Bamidele Solomon called for the establishment of biotechnology development fund.
The fund, he stressed, could help the nation support competent researches and be ready to tackle problems like the bird flu.
He also disclosed that Nigeria in collaboration with Trinity Biotech of the Republic of Ireland will establish a facility at SHESTCO Abuja for the production of test kits for HIV/AIDS and other diseases like HB, malaria and so on.
He added that the Federal Government has approved the sum of $28 million as counterpart commitment for the project.
He also spoke of Nigeria’s collaboration with Shantha Biotechnics Limited of India for the establishment a facility for the production of Hepatitis B vaccine and other vaccines for related diseases like typhoid, polio, DTP and related ailments.
"Government approved the sum of N10 Million in the 2004 capital budget to support carrying out of a detailed feasibility study and fulfilling other MoU requirement."
Posts: 424 | Registered: Apr 2005
| IP: Logged |
posted
28 million is not for XKEM this is to invest in Biotech in general which includes HIV research Bird Flu etc.. nonetheless this stock has huge upside potential and I have been in for several weeks.
-------------------- All men's gains are the fruit of venturing.
~Herodotus Posts: 339 | From: Southern California | Registered: Aug 2005
| IP: Logged |
imakmony2005
unregistered
posted
Getting ready for blastoff here.Dont miss the ride.
IP: Logged |
-------------------- Just looking to have .30 cents more than yesterday...or $$3,000,000...When opportunity knocks, TAKE IT! Posts: 194 | Registered: Mar 2006
| IP: Logged |
-------------------- Just looking to have .30 cents more than yesterday...or $$3,000,000...When opportunity knocks, TAKE IT! Posts: 194 | Registered: Mar 2006
| IP: Logged |
posted
At least .035 by end of week. Watch and see.
Peace
.30CentRunner
-------------------- Just looking to have .30 cents more than yesterday...or $$3,000,000...When opportunity knocks, TAKE IT! Posts: 194 | Registered: Mar 2006
| IP: Logged |
posted
Major breakthrough in fight against sickle cell disease by HERB BOYD Special to the AmNews Originally posted 1/4/2006
With two recent victories under its belt, there is reason for optimism at Xechem, a development stage biopharmaceutical company that has been working diligently to produce and market a drug to fight against Sickle Cell Disease (SCD). Recently, Xechem International announced that it had acquired the exclusive, worldwide licensing rights to a new five-membered heterocyclic anti-sickling compound from Virginia Commonwealth University (VCU). “Early research has shown this anti-sickling agent to be highly effective and a relatively non-toxic treatment for Sickle Cell Disease,” a press release from Xechem said. This new compound, the company stated, will further expand Xechem’s portfolio of products in its fight against this disease that is so common among Africans and African Americans. Acquiring this compound bolsters Xechem’s portfolio, which already includes a license from the National Institute of Pharmaceutical Research and Development, Ministry of Health, Government of Nigeria, for the manufacture, marketing, and distribution of NICOSAN/HEMOXIN, an all natural, phyto-pharmaceutical product that has also shown enormous promise for SCD, according to Xechem. NICOSAN/HEMOXIN has been granted an “Orphan Drug” status by both the U.S. Food and Drug Administration and the European Union’s regulatory body. The company is currently preparing an Investigational New Drug (IND) application for submission to the FDA and EU agencies. ''We know of no existing non-toxic medicines available anywhere in the world for the effective treatment of Sickle Cell Disease,” said Dr. Ramesh C. Pandey, Xechem's Chairman and CEO. “Between our existing product, NICOSAN™/HEMOXIN™, a non-toxic product that has shown excellent results in Phase IIA and Phase IIB clinical trials in Nigeria, and this promising new heterocyclic pharmaceutical agent being developed in collaboration with VCU, Xechem will be in a truly unique position to offer viable and efficacious treatments to patients suffering with this painful and debilitating condition.” Along with the acquisition of the VCU licensing agreement, last week Xechem announced it had settled its anti-trust lawsuit against Bristol-Myers Squibb Company for $4.2 million. The lawsuit, filed two years ago, stemmed from Xechem’s allegations that Bristol Myers “had engaged in anti-competitive practices relating to Xechem’s efforts to manufacture and bring to market the drug paclitaxel, a generic equivalent to Bristol’s cancer drug, TAXOL ®.” The settlement, according to Dr. Pandey, will further his company’s plans to launch its sickle cell drug. “The settlement with Bristol Myers could not have come at a better time for Xechem,” he said. Dr. Pandey has a distinguished career in the biomedical sciences spanning over 35 years and has served with numerous universities, government agencies and pharmaceutical companies worldwide. He came to the United States from India in 1967 with a Ph.D. in medicinal chemistry and spent three post-doctorate years at the University of Illinois-Champaign Urbana, IL with Professor Kenneth L. Rinehart, Jr. Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease, antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its primary focus is on the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of NICOSAN™/HEMOXIN™, which has shown efficacy in the treatment of SCD. Sickle Cell Disease is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body. In Nigeria alone, according to a mini-documentary produced for Xechem by DDO Group LLC Harlem Edit, more than 25% of the population are carriers of the SCD trait and over 4.5 million Nigerians (~5% of the population) are actually afflicted with the disease. Approximately 12 million people, mostly in sub-Saharan Africa, are believed to suffer from this disease worldwide.
-------------------- All men's gains are the fruit of venturing.
~Herodotus Posts: 339 | From: Southern California | Registered: Aug 2005
| IP: Logged |
posted
As we all predicted, this has made a aweseome start to the week !!!!!!
0.0174 already !!!
-------------------- Investment Is Important, but Knowing where to make an Investment in your life makes all Difference Posts: 280 | Registered: Jan 2006
| IP: Logged |
posted
As we all predicted, this has made a aweseome start to the week !!!!!!
0.0174 already !!!
-------------------- Investment Is Important, but Knowing where to make an Investment in your life makes all Difference Posts: 280 | Registered: Jan 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Wink]](wink.gif)
